Apply Give

Other ways to search: Events Calendar | UTHSC

New option approved for erosive esophagitis

Written by Communications and Marketing

|

“For many GERD patients with erosive esophagitis, the response to current treatment is suboptimal, leaving them with incomplete healing and ongoing symptoms,” Colin Howden, MD, of the University of Tennessee College of Medicine in Memphis, said in a statement. “The FDA approval of Voquezna (vonoprazan) provides healthcare providers with a new first-in-class therapeutic option that demonstrated faster healing in the more difficult-to-treat GERD patients with erosive esophagitis.”

Top Publishers